POST Online Media Lite Edition



 

Pfizer makes progress with COVID vaccine for children, Lyme disease vaccine candidate

Christian Fernsby |
Valneva and Pfizer announced further positive Phase 2 results, including booster response, for Lyme disease vaccine candidate VLA15.

Article continues below




The Phase 2 study, VLA15-202, is evaluating the immunogenicity and safety of VLA15 in a Month 0-2-6 vaccination schedule.

The study enrolled 246 healthy adults 18 to 65 years of age in the U.S. As announced in October 20201, the study met its primary endpoint of demonstrating that VLA15 was immunogenic across all dose groups tested and elicited high antibody responses across all serotypes (ST1 - ST6) at one month after completion of the primary vaccination series. Continued evaluation at Month 18 showed that antibody titers declined thereafter across all groups, remaining above baseline but confirming the need for a booster strategy.

VLA15 was safe and well-tolerated across all doses and age groups tested. No related Serious Adverse Events (SAEs) were observed in any treatment group.

Participants who received a complete primary vaccination series with 180 µg doses of VLA15, were invited to continue the study in a booster extension phase and were randomized to receive an additional 180 µg dose of VLA15 (N=39) or placebo (N=19) at Month 18.

VLA15’s acceptable safety profile was confirmed through one-month post-booster. Administration of a booster dose elicited a strong anamnestic response yielding a 2.9-fold (ST3) to 4.2-fold (ST1, ST4) increase (Geometric Mean Fold Rise) in anti-OspA IgG antibody titers compared with titers observed after primary immunization.

All participants seroconverted to anti-OspA IgG after the booster dose, meaning Seroconversion Rates (SCRs) were 100% for all OspA serotypes.

SCR was defined as the rate of subjects that changed from seronegative at baseline to seropositive. Additionally, subjects who were seropositive at baseline needed to show at least a 4-fold increase in anti-OspA IgG compared to baseline titer. Functionality of elicited antibodies was demonstrated by Serum Bactericidal activity Assays, leading to SCRs ranging from 86.8% (ST2) to 100.0% (ST3) after the booster. The study is continuing to monitor persistence of antibody responses.

Pfizer and BioNTech announced they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in children 5 to <12 years of age.

The Companies announced positive topline results from the pivotal trial on September 20, 2021. In the trial, which included 2,268 participants 5 to <12 years of age, the vaccine demonstrated a favorable safety profile and elicited robust neutralizing antibody responses using a two-dose regimen of 10 μg doses. These results – the first from a pivotal trial of any COVID-19 vaccine in this age group – were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age, who were immunized with 30 μg doses. The 10 μg dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to <12 years of age.

These data have been shared with the FDA for the Agency’s initial review. A formal submission to request Emergency Use Authorization (EUA) of the companies’ COVID-19 vaccine in children 5 to <12 years of age is expected to follow in the coming weeks. Submissions to the European Medicines Agency (EMA) and other regulatory authorities are also planned.

Topline immunogenicity and safety readouts for the other two age cohorts from the trial – children 2 to <5 years of age and children 6 months to <2 years of age – are expected as soon as the fourth quarter of this year.

Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer reviewed publication.

The Phase 1/2/3 trial initially enrolled up to 4,500 children ages 6 months to <12 years of age in the United States, Finland, Poland, and Spain from more than 90 clinical trial sites.

It was designed to evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech vaccine on a two-dose schedule (approximately 21 days apart) in three age groups: ages 5 to <12 years; ages 2 to <5 years; and ages 6 months to <2 years. Based on the Phase 1 dose-escalation portion of the trial, children 5 to <12 years of age received a two-dose schedule of 10 μg each while children under age 5 received a lower 3 μg dose for each injection in the Phase 2/3 study. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.


What to read next

News screening device shows promise for Lyme disease
Lyme disease prevalence increasing, now present in new U.S. States
Lyme bacteria survive 28-day course of antibiotics months after infection

Flooding concerns in Puerto Rico; thunderstorms across southeast U.S.

 
The main weather feature and focus for showers and thunderstorms through this weekend will be a cold front progressing across the East and stalling between the Southeast and southern Texas.
 
 

Latest

Concept Medical announces enrollment of first patient in "MAGICAL-ISR" ide study in U.S.
U.S. oil rig count up by 5 to 511
Rhode Island Governor, State Police promote safe travel across Washington Bridge
Governor Abbott met with Samsung executives to discuss billions invested in Texas

NEWS

California: Nearly 500 arrests, 160,000 stolen goods recovered in just 3 months

Romania: EPPO probes public officials in investigation into €160 000 fraud involving employment funds
EPPO: 3 convicted of evading €3.1 million in customs duties on imported e-bikes
Romania: EPPO conducted searches in investigation into €1.7 million fraud involving irrigation systems
U.S.: Pacific storm over west
4.8 magnitude earthquake rattles New Jersey and New York
 

BUSINESS

U.S. drillers cut oil and gas rigs to 620

Australia: East coast gas surplus expected in Q3 2024
Kuwait-Saudi rail link to be ready by 2028, says report
Cambodia approves investment projects worth $2.2 in Q1
Venice to charge day trip tourists 5 euros
Commission opens two in-depth investigations in solar photovoltaic sector
 

Trending Now

Coca-Cola Company to create approximately 250 new jobs in Town of Webster

Governor Abbott met with Samsung executives to discuss billions invested in Texas

Concept Medical announces enrollment of first patient in "MAGICAL-ISR" ide study in U.S.

Egypt to establish free zone for yachts along Red Sea coast


POLITICS

Egypt to establish free zone for yachts along Red Sea coast

UK Exports Minister visits Latin America to boost trade and unlock billions worth of exports
Argentina, Brazil in talks to reverse Bolivian gas pipeline amid shortage
Trudeau offers $6 billion to provinces to build housing
€1 billion Greek State aid measures to support renewable energy generation and storage projects
North Carolina reaches electric vehicle registration goals two years early
 

Today We Recommend

Egypt to establish free zone for yachts along Red Sea coast


Highlights 

Nokia Q1 sales down

UnitedHealth Q1 $99.8 billion

Johnson & Johnson Q1 earnings $5.3bn


COMPANIES

Coca-Cola Company to create approximately 250 new jobs in Town of Webster

99 Cents Only Stores to close all 371 stores
Alaska Airlines says Boeing paid $160 mln for 737 Max 9 grounding
Lindsay announces agreement to acquire minority interest in Pessl Instruments
Saint-Gobain to acquire Bailey for $650 million
Farmers Mutual Hail to acquire Global Ag from AXA XL
 

CAREERS

MainStreaming appoints Tassilo Raesig as COO

BioArctic AB proposes for election board members and chairperson
TerraPay names Marco Boldini as EVP and global head of governmental affairs
Farmers Insurance appoints John Griek as CFO
PA Media Group appoints Emily Shelley as new CEO
BioNTech appoints Annemarie Hanekamp as chief commercial officer
 

ECONOMY

Slovenia's economy expected to grow 0.9 pct in Q1

Italy faces deficit infringement procedure
Real GDP increased in all 50 U.S. states
Inflation continues to decline in Germany
UK house prices log unexpected fall
South Korea's FDI logs double digit growth in Q1
 

EARNINGS

Nokia Q1 sales down

UnitedHealth Q1 $99.8 billion
Johnson & Johnson Q1 earnings $5.3bn
Dollarama Q4 sales increased 11.3%
Conagra Brands Q3 sales decreased 1.7%
Liebherr finished 2023 business year with record revenue of €14,042 million
 

OP-ED

Micromanaging is the worst enemy of efficiency and teamwork

Niger set to monetize massive gas reserves through Saharan natural gas pipeline
Putting the brakes on EV folly that choked the market
Oil discovery in Kavango Basin may mean huge benefits for Namibians
Cape Town and Dubai battle over Africa's energy future
Is America going to lose its superpower status?
 

AGRIFISH

FAO Food Price Index rises in March

Australia grants license for GM bananas amid Fusarium Wilt TR4 concerns
Indian government allows exports of 10,000 tons of onions to UAE
Analytical survey: Sales of agricultural lands in Ukraine up 50% in February
Decline in Norwegian seafood exports in Q1
Tanzania's first fishing harbor to be completed in 2025
 

LEADERSHIP

Study finds workers misjudge wage markets

Some organizations may need to expand their hierarchical structures earlier than others
Study finds there's right way and wrong way to deliver negative feedback in workplace
Allyship is critical and its needs appreciation
Generating 'buzz' about new products can influence their success
Hiring 'problem directors' can knock up to 64% off firm's value
 

CRIME

HSBC pays penalties for alleged breaches of Consumer Data Right rules

Sanofi to settle thousands of Zantac cancer lawsuits
Former asset manager and board member of Geneva private bank referred to Swiss Federal Criminal Court
South Africa: SAP ordered to pay SIU $26m over 'invalid' Eskom contracts
Former Steinhoff director appears in court for $1.1b fraud, racketeering
Genesis agrees to pay $21 million penalty to settle SEC charges
 

Magazine

TRAVEL

Buna channels, an unreal and beautiful part of Bosnia and Herzegovina

JW Marriott unveils Mindful Haven with opening of JW Marriott Hotel Nairobi
Sotheby's Sports Week returns with fantastic artifacts
Red Roof properties open in Michigan
Treyam, your premier lagoon destination in Saudi Arabia
San Francisco: SkyStar wheel on Fisherman’s Wharf to stay for another 18 months
 

SEA, LAND, AIR

2025 Chevrolet Equinox stands apart with fresh looks and capability

Hill Helicopters HX50, luxury in the sky
Opel Movano becomes fully equipped camper van
Porsche Panamera, new hybrid variants
Dodge Charger, 670 horsepower of electric
Pagani Huayra R Evo, 900 hp from 770 Nm
 

DESIGN

Cold night, hot fire pit, cool entertainment

Embellish your home with PVC panels
You'll have to hurry if you want one of 20 new Louis Vuitton watches
Luxury duvet looks good, fells good and keeps you healthy
Vacheron Constantin, watches for life and more
Schüller kitchens, where functionality marries design
 

GADGETS

reMarkable 2, monochrome tablet for your thoughts and your eyes

OnePlus Ace 3V, first with Snapdragon 7 Plus Gen 3
ASUS Zenfone 11 Ultra, flagship with a reason
Samsung Galaxy S24 is photography powerhouse
Casette tapes are making a big comeback, and so are portable players
Neumann TLM 103, standard microphone for both voice and music
 

HEALTH

India launches first home-grown gene therapy for cancer

UK scientists win funding for 'cancer detecting' Lollipops
State to cover rare disease treatment costs in Bulgaria
Type 1 diabetes patients in England to receive 'artificial pancreas' as medication
Pilot study shows ketogenic diet improves severe mental illness
Texas reports possibly U.S. first human case of bird flu linked to cattle
 

MEANTIME

Rare species of wild bees discovered in Berlin

SLAC completes construction of largest digital camera ever built for astronomy
Solar eclipse next week in U.S., Mexico and Canada
Gravitational waves may have made human life possible
Astronomers unveil strong magnetic fields spiraling at the edge of Milky Way's central black hole
Scientists on hunt for evidence of quantum gravity's existence at South Pole